{"id":85624,"date":"2017-10-23T11:00:30","date_gmt":"2017-10-23T11:00:30","guid":{"rendered":"http:\/\/mostafa.openonline.co.uk\/?guid=2977b784cea9ecebb109856b2d2ebcfc"},"modified":"2017-10-23T11:00:30","modified_gmt":"2017-10-23T11:00:30","slug":"news-story-making-viral-vectors-for-advanced-therapies-apply-for-funding","status":"publish","type":"post","link":"https:\/\/mostafa.openonline.co.uk\/?p=85624","title":{"rendered":"News story: Making viral vectors for advanced therapies: apply for funding"},"content":{"rendered":"<div class=\"govspeak\">\n<p>Innovate UK has up to \u00a316 million to invest in capital projects that support the growth of manufacturing capacity for viral vectors used in cell and gene therapies.<\/p>\n<h2 id=\"commercial-opportunities-in-advanced-therapies\">Commercial opportunities in advanced therapies<\/h2>\n<p>Advanced therapy medicinal products are emerging medicines that use cells, genes or engineered tissues to treat patients.<\/p>\n<p>These therapies usually involve delivery of the treatment by a virus. The therapeutic gene is carried in a viral vector.<\/p>\n<p>It is estimated that the global market for regenerative medicine and cell therapies could be more than $67 billion by 2020 and for gene therapy $11 billion by 2025. While the UK is at the forefront of research into these new therapies, there is a shortage of capacity for making viral vectors. We need to act to take advantage of the commercial opportunities.<\/p>\n<p>The funding for this competition is under the government\u2019s Industrial Strategy Challenge Fund to develop first-of-a-kind technologies for the manufacture of medicines.<\/p>\n<div class=\"call-to-action\">\n<p><a href=\"https:\/\/www.gov.uk\/government\/collections\/industrial-strategy-challenge-fund-joint-research-and-innovation\">Find out more about the Industrial Strategy Challenge Fund.<\/a><\/p>\n<\/div>\n<h2 id=\"encouraging-public-and-private-partnerships\">Encouraging public and private partnerships<\/h2>\n<p>Funding in this competition is for capital investment in equipment that can be used for making viral vectors. This can include refurbishment.<\/p>\n<p>Projects must:<\/p>\n<ul>\n<li>advance UK ability to produce viral vectors for use in advanced therapies<\/li>\n<li>encourage partnerships between public and private organisations and maximise further investment<\/li>\n<\/ul>\n<p>Successful projects are likely to include ones that:<\/p>\n<ul>\n<li>create infrastructure that fast-tracks research, development, production and commercialisation of viral vectors<\/li>\n<li>increase UK commercial capacity<\/li>\n<li>increase competitiveness of the lead business<\/li>\n<\/ul>\n<div class=\"call-to-action\">\n<p><a href=\"https:\/\/www.gov.uk\/government\/collections\/innovate-uk-health-and-life-sciences\">Find out more about how we support innovation in health and life sciences.<\/a><\/p>\n<\/div>\n<h2 id=\"competition-information\">Competition information<\/h2>\n<ul>\n<li>the competition is open, and the deadline for registration is midday on 8 November 2017<\/li>\n<li>projects must be led by a business with a viral vector manufacturing facility, working alone or with partners<\/li>\n<li>we expect projects will range in size from total costs of \u00a32 million to \u00a36 million<\/li>\n<li>businesses can attract up to 50% of their project costs<\/li>\n<\/ul>\n<div class=\"call-to-action\">\n<p><a rel=\"external\" href=\"https:\/\/apply-for-innovation-funding.service.gov.uk\/competition\/76\/overview\">Find out more about this competition and apply.<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Businesses can apply for a share of \u00a316 million for manufacturing viral vectors for cell and gene therapy &#8211; part of the Industrial Strategy Challenge Fund.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/85624"}],"collection":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=85624"}],"version-history":[{"count":0,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/85624\/revisions"}],"wp:attachment":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=85624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=85624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=85624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}